NASDAQ:MRNS - Marinus Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.98 +0.16 (+4.19 %)
(As of 03/26/2019 04:00 PM ET)
Previous Close$3.82
Today's Range$3.83 - $3.99
52-Week Range$2.36 - $10.54
Volume373,868 shs
Average Volume782,003 shs
Market Capitalization$209.03 million
P/E Ratio-4.42
Dividend YieldN/A
Beta3.2
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRNS
CUSIPN/A
Phone484-801-4670

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.30 per share

Profitability

Net Income$-36,730,000.00

Miscellaneous

EmployeesN/A
Market Cap$209.03 million
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable

Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced its quarterly earnings data on Monday, March, 11th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.26) by $0.02. View Marinus Pharmaceuticals' Earnings History.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Marinus Pharmaceuticals.

What price target have analysts set for MRNS?

7 analysts have issued 12-month price targets for Marinus Pharmaceuticals' stock. Their predictions range from $5.00 to $29.00. On average, they anticipate Marinus Pharmaceuticals' stock price to reach $16.1429 in the next year. This suggests a possible upside of 305.6% from the stock's current price. View Analyst Price Targets for Marinus Pharmaceuticals.

What is the consensus analysts' recommendation for Marinus Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marinus Pharmaceuticals.

What are Wall Street analysts saying about Marinus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Marinus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. " (3/16/2019)
  • 2. Mizuho analysts commented, "We highlighted our expectations for the phase 2 data in a previous note (available here). Magnolia is a multiple dose escalation study with ~60 patients randomized 1:1 with multiple dose cohorts and therefore not designed to hit statistical significance, in contrast to the phase 2 trial of Sage Therapeutics (SAGE, not rated) which was designed with a specific dose of brexanolone. In our view, the most important information to look for in the results will be a signal of efficacy along with information on a specific dose to be taken into Magnolia study." (9/25/2018)
  • 3. Cantor Fitzgerald analysts commented, "Given the compelling Phase 2 data announced in CDD, market size potential in PPD, and undervaluation relative to peers, we believe Marinus shares offer a compelling risk- reward profile. The company has three important data read-outs remaining in 4Q18, which we believe could become significant catalysts for the shares. Valuation Summary We arrive at our 12-month PT of $19/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from ganaxolone for the treatment of postpartum depression and CDKL5 deficiency disorder." (9/17/2018)

Has Marinus Pharmaceuticals been receiving favorable news coverage?

Media headlines about MRNS stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Marinus Pharmaceuticals earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days.

Who are some of Marinus Pharmaceuticals' key competitors?

What other stocks do shareholders of Marinus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Verastem (VSTM), Micron Technology (MU), Novavax (NVAX), XOMA (XOMA), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Exelixis (EXEL), SCYNEXIS (SCYX), Advanced Micro Devices (AMD) and Corbus Pharmaceuticals (CRBP).

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the folowing people:
  • Mr. Christopher Michael Cashman, Exec. Chairman, CEO & Pres (Age 62)
  • Mr. Edward F. Smith, CFO, VP, Treasurer & Sec. (Age 48)
  • Dr. Lorianne K. Masuoka, Chief Medical Officer (Age 58)
  • Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations
  • Mr. Thomas J. Lyons, VP of Corp., Bus. Devel. & Commercial Planning

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (11.24%), BlackRock Inc. (6.02%), 683 Capital Management LLC (3.33%), Tekla Capital Management LLC (1.86%), Partner Fund Management L.P. (1.29%) and Orbimed Advisors LLC (1.23%). Company insiders that own Marinus Pharmaceuticals stock include Bain Capital Life Sciences Inv, Christopher Michael Cashman and Edward F Smith. View Institutional Ownership Trends for Marinus Pharmaceuticals.

Which institutional investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., BlackRock Inc., Orbimed Advisors LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP and Bank of New York Mellon Corp. Company insiders that have sold Marinus Pharmaceuticals company stock in the last year include Christopher Michael Cashman and Edward F Smith. View Insider Buying and Selling for Marinus Pharmaceuticals.

Which institutional investors are buying Marinus Pharmaceuticals stock?

MRNS stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Tekla Capital Management LLC, Fosun International Ltd, Highbridge Capital Management LLC, 683 Capital Management LLC, Monashee Investment Management LLC, Millennium Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Marinus Pharmaceuticals.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $3.98.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $209.03 million. The biopharmaceutical company earns $-36,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

What is Marinus Pharmaceuticals' official website?

The official website for Marinus Pharmaceuticals is http://www.marinuspharma.com.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 170 N. Radnor Chester Rd Suite 250, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]


MarketBeat Community Rating for Marinus Pharmaceuticals (NASDAQ MRNS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  480
MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote "Outperform" if you believe MRNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Featured Article: Compound Interest

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel